Analyzing Citius Oncology (NASDAQ:CTOR) and Windtree Therapeutics (NASDAQ:WINT)

Windtree Therapeutics (NASDAQ:WINT) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership.

Institutional & Insider Ownership

29.3% of Windtree Therapeutics shares are held by institutional investors. Comparatively, 70.5% of Citius Oncology shares are held by institutional investors. 0.2% of Windtree Therapeutics shares are held by insiders. Comparatively, 9.8% of Citius Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Windtree Therapeutics and Citius Oncology, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Windtree Therapeutics	0	0	0	0	0.00
Citius Oncology	1	0	2	0	2.33

Citius Oncology has a consensus price target of $6.00, suggesting a potential upside of 945.66%. Given Citius Oncology’s stronger consensus rating and higher probable upside, analysts clearly believe Citius Oncology is more favorable than Windtree Therapeutics.

Profitability

This table compares Windtree Therapeutics and Citius Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Windtree Therapeutics	N/A	-207.34%	-50.19%
Citius Oncology	N/A	-99.47%	-42.16%

Risk and Volatility

Windtree Therapeutics has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Comparatively, Citius Oncology has a beta of 3.47, meaning that its share price is 247% more volatile than the S&P 500.

Valuation & Earnings

This table compares Windtree Therapeutics and Citius Oncology”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Windtree Therapeutics	N/A	N/A	-$1.79 million	($8.77)	-0.00
Citius Oncology	N/A	N/A	-$24.76 million	($0.47)	-1.22

Citius Oncology is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Citius Oncology beats Windtree Therapeutics on 9 of the 11 factors compared between the two stocks.

About Windtree Therapeutics

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee’s Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.

About Citius Oncology

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.